Skip to content

US · BEAM · BIOTECHNOLOGY

Beam Therapeutics Inc. (BEAM) intrinsic value and stock valuation

$20.90as of 2026-11-21 · Mkt cap 2.78B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Beam Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values BEAM with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from BEAM’s statements →

Beam Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 beamtx.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$139.7M+487.3% 5y CAGRd
20172025
Net income
-$-79.99M
20172025
Free cash flow
-$-360.05M
20172025
Total equity
$1.24B+38.2% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$139.7M$63.5M$377.7M$60.9M$51.8M
Operating income-$-383.69M-$-415.57M-$-176.49M-$-338.48M-$-392.46M
Net income-$-79.99M-$-376.74M-$-132.53M-$-289.09M-$-370.64M
EPSd-$-808.71K-$-4.58M-$-1.72M-$-4.13M-$-5.77M
Operating cash flow-$-345.1M-$-347.25M-$-149.19M$22.5M-$-66.27M
Capital expenditure-$-14.95M-$-8.95M-$-33.73M-$-48.95M-$-46.81M
Free cash flow-$-360.05M-$-356.19M-$-182.93M-$-26.42M-$-113.08M
Total assets$1.48B$1.1B$1.46B$1.34B$1.47B
Total debt$293.9M$161.4M$172.7M$179M$147.6M
Net debt-$-1.06M-$-120.54M-$-263.21M-$-53.76M-$-412.35M
Total equity$1.24B$733.5M$981.3M$733.5M$826.7M
Cash and short-term investments$1.25B$850.7M$1.19B$1.08B$965.7M
Income statement
20252024202320222021
Revenue$139.7M$63.5M$377.7M$60.9M$51.8M
Cost of revenue$22.3M$367.6M$0.00$311.6M$232.1M
Gross profit$117.5M-$-304.04M$377.7M-$-250.67M-$-180.29M
Research and development expenses$409.6M$367.6M$437.4M$311.6M$387.1M
Selling, general and administrative expenses$113.8M$111.5M$116.8M$87.8M$57.2M
Other expenses-$-22.29M-$-367.56M$0.00-$-311.59M-$-232.13M
Operating expenses$501.1M$111.5M$554.2M$87.8M$212.2M
Cost and expenses$523.4M$479.1M$554.2M$399.4M$444.3M
Interest income$0.00$49.1M$46.7M$15.3M$0.00
Interest expense$43.7M$0.00$0.00$0.00$0.00
Depreciation and amortization$6.34M$21.9M$29.5M$14.2M$7.45M
Ebitda-$-29.92M-$-354.78M-$-101.63M-$-271.53M-$-230.06M
Operating income-$-383.69M-$-415.57M-$-176.49M-$-338.48M-$-392.46M
Total other income/expenses, net$303.7M$38.9M$45.3M$52.8M$21.8M
Income before tax-$-79.99M-$-376.7M-$-131.16M-$-285.68M-$-370.64M
Income tax expense$0.00$40K$1.37M$3.41M$0.00
Net income-$-79.99M-$-376.74M-$-132.53M-$-289.09M-$-370.64M
Weighted average shares outstanding$98.9M$82.3M$77.2M$70M$64.2M
Weighted average diluted shares outstanding$98.9M$82.3M$77.2M$70M$64.2M
Balance sheet
20252024202320222021
Cash and short-term investments$1.25B$850.7M$1.19B$1.08B$965.7M
Net receivables$0.00$0.00$0.00$0.00$300M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$1.27B$878.2M$1.21B$1.09B$1.27B
Property, plant and equipment, net$205.2M$216.3M$237.8M$234.1M$187M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$6.68M$0.00$0.00$0.00$0.00
Total non-current assets$212.5M$225.7M$248.7M$248.8M$201.5M
Total assets$1.48B$1.1B$1.46B$1.34B$1.47B
Accounts payable$10.2M$3.87M$1.62M$9.03M$7.47M
Short-term debt$14.4M$13.5M$12.8M$10.4M$9.83M
Deferred revenue$6.66M$108.9M$68.7M$136M$86.3M
Total current liabilities$96.9M$182.1M$205.6M$223.6M$213.4M
Long-term debt$279.5M$148M$159.9M$168.6M$137.8M
Deferred revenue, non-current$0.00$33.2M$109.9M$202.2M$262.3M
Total non-current liabilities$145.9M$188.2M$272.8M$384.6M$434.3M
Capital lease obligations$139.8M$161.4M$172.7M$179M$142.4M
Total liabilities$242.8M$370.3M$478.4M$608.2M$647.7M
Common stock$1.02M$840K$820K$710K$680K
Retained earnings-$-1.64B-$-1.57B-$-1.19B-$-1.06B-$-768.27M
Accumulated other comprehensive income (loss)$1.11M$680K$600K-$-2.43M-$-50K
Total equity$1.24B$733.5M$981.3M$733.5M$826.7M
Total investments$956.9M$568.8M$754M$845.4M$405.7M
Total debt$293.9M$161.4M$172.7M$179M$147.6M
Net debt-$-1.06M-$-120.54M-$-263.21M-$-53.76M-$-412.35M
Cash flow statement
20252024202320222021
Net income-$-79.99M-$-376.74M-$-132.53M-$-289.09M-$-370.64M
Depreciation and amortization$22.3M$21.9M$20M$14.2M$7.45M
Stock-based compensation$94.2M$120.7M$98.7M$84.3M$43.6M
Change in working capital-$-131.02M-$-110.22M-$-116.45M$251.6M$111.3M
Accounts receivable$0.00$0.00$0.00$300M-$-300M
Inventory$0.00$0.00$0.00-$-300M$0.00
Accounts payable$6.04M$1.81M-$-7.58M$2.37M$820K
Net cash provided by operating activities-$-345.1M-$-347.25M-$-149.19M$22.5M-$-66.27M
Investments in property, plant and equipment-$-14.95M-$-8.95M-$-33.73M-$-48.95M-$-46.81M
Acquisitions, net-$-80K$0.00$0.00$412.4M$620K
Net cash used for investing activities-$-121.44M$185M$71.8M-$-461.34M-$-294.14M
Common stock issued$478.1M$8.22M$270.2M$108.3M$757.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$478.1M$7.74M$276.5M$111.6M$756.1M
Net change in cash$11.5M-$-154.5M$199.1M-$-327.22M$395.7M
Cash at end of period$301.6M$290.1M$444.6M$245.5M$572.7M
Operating cash flow-$-345.1M-$-347.25M-$-149.19M$22.5M-$-66.27M
Capital expenditure-$-14.95M-$-8.95M-$-33.73M-$-48.95M-$-46.81M
Free cash flow-$-360.05M-$-356.19M-$-182.93M-$-26.42M-$-113.08M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Beam Therapeutics Inc.

        Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

        CEO
        John Evans
        Employees
        511
        Beta
        2.18

        Explore

        Frequently asked questions

        What is the intrinsic value of Beam Therapeutics Inc. (BEAM)?

        Beam Therapeutics Inc. (BEAM) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BEAM undervalued?

        BEAM trades at a price of $20.90 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.